Marketed drugs used for the management of hypercholesterolemia as anticancer armament

Abstract

The design of novel pharmacologic agents as well as their approval for sale in markets all over the world is a tedious and pricey process. Inevitably, oncologic patients commonly experience unwanted effects of new anticancer drugs, while the acquisition of clinical experience for these drugs is largely based on doctor–patient partnership which is not always effective. The repositioning of marketed non-antineoplastic drugs that hopefully exhibit anticancer properties into the field of oncology is a challenging option that gains ground and attracts preclinical and clinical research in an effort to override all these hindrances and minimize the risk for reduced efficacy and/or personalized toxicity. This review aims to present the anticancer properties of drugs used for the management of hypercholesterolemia. A global view of the antitumorigenicity of all marketed antihypercholesterolemic drugs is of major importance, given that atherosclerosis, which is etiologically linked to hypercholesterolemia, is a leading worldwide cause of morbidity and mortality, while hypercholesterolemia and tumorigenesis are known to be interrelated. In vitro, in vivo and clinical literature data accumulated so far outline the mechanistic basis of the antitumor function of these agents and how they could find application at the clinical setting.

Statins and Colorectal Cancer Risk: A Population-Based Case-Control Study and Synthesis of the Epidemiological Evidence

“…The protection observed for rosuvastatin differs substantially from the one observed for the rest of statins. Despite the fact that complex anti-tumor mechanisms have been specifically described for rosuvastatin in in-vivo studies [ 39 ], the extent of those in the prevention of CRC is unknown. Furthermore, since pleiotropic effects are a beneficial consequence of the inhibition of HMG-CoA reductase, it would be pharmacologically plausible that the higher the intensity of such inhibition the more enhanced pleiotropic effects [ 16 ].…”

MicroRNA-488 serves as a diagnostic marker for atherosclerosis and regulates the biological behavior of vascular smooth muscle cells

“…AS is a chronic systemic inflammatory disease, and it is also the most common death disease in the world. The death toll is more than that of all cancers combined [ 20 , 21 ]. It is the main pathological basis of ischemic cardiovascular and cerebrovascular diseases such as coronary heart disease, cerebrovascular disease, and thromboembolic disease [ 22 ].…”

Improving the effectiveness of anti-aging modalities by using the constrained disorder principle-based management algorithms

“…Meta-analysis of 92 placebo-controlled and active-comparator trials demonstrated that statins are effective for primary and secondary cardiovascular prevention, reducing major coronary events and all-cause mortality by reducing oxidative stress and inflammatory markers ( Naci et al, 2013 ; Shimomura et al, 2016 ; Gilbert et al, 2017 ). Statins induce apoptosis, cause cytostatic and antiproliferative effects, augment anticarcinogenic properties of standard chemotherapies, and attenuate cancer cell migration and invasion ( Papanagnou et al, 2017 ).…”